Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Structure-based drug design using the crystal structure of human 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) led to the discovery of novel, selective, and the most potent inhibitors of 17beta-HSD1 reported to date. Compounds 1 and 2 contain a side chain with an m-pyridylmethyl-amide functionality extended from the 16beta position of a steroid scaffold. A mode of binding is proposed for these inhibitors, and 2 is a steroid-based 17beta-HSD1 inhibitor with the potential for further development.

Original publication

DOI

10.1021/jm049045r

Type

Journal article

Journal

J Med Chem

Publication Date

21/04/2005

Volume

48

Pages

2759 - 2762

Keywords

17-Hydroxysteroid Dehydrogenases, Antineoplastic Agents, Cell Line, Tumor, Crystallography, X-Ray, Estrone, Humans, Models, Molecular, Molecular Structure, Pyridines, Stereoisomerism, Structure-Activity Relationship